Human Insulin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Human Insulin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Human Insulin Market
The human insulin market size was valued at USD 19.19 billion in 2023, and the market is now projected to grow from USD 19.69 billion in 2024 to USD 25.08 billion by 2032, exhibiting a CAGR of 3.1% during the forecast period of 2023-2032.
The key players in the market faced a significant revenue decline due to the COVID-19 pandemic, which had a direct impact on their human insulin market growth. Factors like the reduction in diabetes testing volume, decreased attention to disease management beyond COVID-19, and other critical parameters directly influenced insulin sales, particularly in the initial half of 2020. Consequently, these players experienced a 5% decline in revenue, reflecting a contraction in their market growth for the year 2020.
Obesity and a sedentary life-style are the primary elements responsible for the global upward thrust in diabetes. The occurrence of diabetes has visible large boom in current decades and is projected to further increase extensively in the coming years. Diabetes is recognized as one of the main causes of dying and incapacity worldwide, with about 1.5 million deaths attributed to it, as in keeping with WHO facts. While the prevention of kind 2 diabetes is possible, it stays a major challenge for healthcare professionals. This scenario underscores the critical importance of information and addressing those factors to undoubtedly impact market proportion inside the diabetes control and prevention area.
The launch of insulin analogues has supplied replacement techniques proposed to mimic everyday human body structure greater intently. Various research have verified that their pharmacodynamics and pharmacokinetic profiles are nearer, resulting in quicker offset and onset of insulin impact in comparison to ordinary human insulin.
Comprehensive Analysis of Human Insulin Market
Analogue insulin ruled the marketplace in 2023, thanks to the growing blessings analogue insulin affords compared to traditional human insulin. According to various published articles and whitepapers, analog insulin has better adherence to therapy and glycemic manipulate. In phrases of kind, the type 1 diabetes phase is expected to exhibit a robust CAGR due to the increasing prevalence of diabetes.
North America generated a revenue of USD 8.81 billion in 2023. The strong presence of the primary insulin producers, strong competition some of the groups, and the growing occurrence of kind 1 diabetes are some elements using North America's insulin drug marketplace.
The top gamers in the market play a critical position in the healthcare enterprise assuring commercial prospectus boom and putting marketplace standards. These gamers encompass, Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi (France), BIOTON S.A. (Poland), Gan and Lee Pharmaceuticals (China), Biocon (India), Tonghua Dongbao Pharmaceutical (China), Julphar (UAE), Wockhardt (India) these market gamers provide a stage-gambling competitive landscape.
Novo Nordisk partnered with Aspen Pharmacare Holdings Limited (Aspen) and Aspen SA Operations (Pty) Ltd in South Africa for the status quo of human insulin manufacturing inside the country.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 4.1% from 2024 to 2032
Unit Value (USD Billion); Volume (Million Ton)
Segmentation By Type
High-density Polyethylene (HDPE)/ Medium-density Polyethylene (MDPE)
Low-Density Polyethylene (LDPE)
Linear Low Density Polyethylene (LLDPE)
By End-use Industry
Packaging
Automotive
Infrastructure & Construction
Consumer Goods/Lifestyle
Healthcare & Pharmaceuticals
Electrical & Electronics
Agriculture
Others
By Geography
North America (By Type, By End-use Industry, By Country)
- U.S.
- Canada
Europe (By Type, By End-use Industry, By Country)
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific (By Type, By End-use Industry, By Country)
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Type, By End-use Industry, By Country)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Type, By End-use Industry, By Country)
- South Arabia
- UAE
- Egypt
- Rest of the Middle East & Africa
Table of Contents
174 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Pipeline Analysis, By Key Players
- 4.2. Pricing Analysis, By Key Countries, 2023
- 4.3. Prevalence of Diabetes, By Key Countries, 2023
- 4.4. Brand Analysis – By Key Countries
- 4.5. Key Market Strategies, By Key Players
- 4.6. Overview of Regulatory Scenario – For Key Countries/Regions
- 4.7. Impact of COVID-19 on the Market
- 5. Global Human Insulin Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Type
- 5.1.1. Analogue Insulin
- 5.1.1.1. Long-acting
- 5.1.1.2. Fast-acting
- 5.1.1.3. Premix
- 5.1.2. Traditional Human Insulin
- 5.1.2.1. Long-acting
- 5.1.2.2. Short-acting
- 5.1.2.3. Fast-acting
- 5.1.2.4. Premix
- 5.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 5.2.1. Diabetes Type 1
- 5.2.2. Diabetes Type 2
- 5.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail & Online Pharmacies
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East and Africa
- 6. North America Human Insulin Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Type
- 6.1.1. Analogue Insulin
- 6.1.1.1. Long-acting
- 6.1.1.2. Fast-acting
- 6.1.1.3. Premix
- 6.1.2. Traditional Human Insulin
- 6.1.2.1. Long-acting
- 6.1.2.2. Short-acting
- 6.1.2.3. Fast-acting
- 6.1.2.4. Premix
- 6.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 6.2.1. Diabetes Type 1
- 6.2.2. Diabetes Type 2
- 6.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Retail & Online Pharmacies
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.1.1. By Diabetes Type
- 6.4.2. Canada
- 6.4.2.1. By Diabetes Type
- 7. Europe Human Insulin Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Type
- 7.1.1. Analogue Insulin
- 7.1.1.1. Long-acting
- 7.1.1.2. Fast-acting
- 7.1.1.3. Premix
- 7.1.2. Traditional Human Insulin
- 7.1.2.1. Long-acting
- 7.1.2.2. Short-acting
- 7.1.2.3. Fast-acting
- 7.1.2.4. Premix
- 7.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 7.2.1. Diabetes Type 1
- 7.2.2. Diabetes Type 2
- 7.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail & Online Pharmacies
- 7.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.4.1. U.K.
- 7.4.1.1. By Diabetes Type
- 7.4.2. Germany
- 7.4.2.1. By Diabetes Type
- 7.4.3. France
- 7.4.3.1. By Diabetes Type
- 7.4.4. Italy
- 7.4.4.1. By Diabetes Type
- 7.4.5. Spain
- 7.4.5.1. By Diabetes Type
- 7.4.6. Scandinavia
- 7.4.6.1. By Diabetes Type
- 7.4.7. Rest of Europe
- 7.4.7.1. By Diabetes Type
- 8. Asia Pacific Human Insulin Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Type
- 8.1.1. Analogue Insulin
- 8.1.1.1. Long-acting
- 8.1.1.2. Fast-acting
- 8.1.1.3. Premix
- 8.1.2. Traditional Human Insulin
- 8.1.2.1. Long-acting
- 8.1.2.2. Short-acting
- 8.1.2.3. Fast-acting
- 8.1.2.4. Premix
- 8.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 8.2.1. Diabetes Type 1
- 8.2.2. Diabetes Type 2
- 8.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail & Online Pharmacies
- 8.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.4.1. China
- 8.4.1.1. By Diabetes Type
- 8.4.2. Japan
- 8.4.2.1. By Diabetes Type
- 8.4.3. India
- 8.4.3.1. By Diabetes Type
- 8.4.4. Australia
- 8.4.4.1. By Diabetes Type
- 8.4.5. Southeast Asia
- 8.4.5.1. By Diabetes Type
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Diabetes Type
- 9. Latin America Human Insulin Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Type
- 9.1.1. Analogue Insulin
- 9.1.1.1. Long-acting
- 9.1.1.2. Fast-acting
- 9.1.1.3. Premix
- 9.1.2. Traditional Human Insulin
- 9.1.2.1. Long-acting
- 9.1.2.2. Short-acting
- 9.1.2.3. Fast-acting
- 9.1.2.4. Premix
- 9.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 9.2.1. Diabetes Type 1
- 9.2.2. Diabetes Type 2
- 9.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail & Online Pharmacies
- 9.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.4.1. Brazil
- 9.4.1.1. By Diabetes Type
- 9.4.2. Mexico
- 9.4.2.1. By Diabetes Type
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Diabetes Type
- 10. Middle East & Africa Human Insulin Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Type
- 10.1.1. Analogue Insulin
- 10.1.1.1. Long-acting
- 10.1.1.2. Fast-acting
- 10.1.1.3. Premix
- 10.1.2. Traditional Human Insulin
- 10.1.2.1. Long-acting
- 10.1.2.2. Short-acting
- 10.1.2.3. Fast-acting
- 10.1.2.4. Premix
- 10.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 10.2.1. Diabetes Type 1
- 10.2.2. Diabetes Type 2
- 10.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail & Online Pharmacies
- 10.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.4.1. GCC
- 10.4.1.1. By Diabetes Type
- 10.4.2. South Africa
- 10.4.2.1. By Diabetes Type
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Diabetes Type
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2023)
- 11.2. Company Profiles
- 11.2.1. Novo Nordisk A/S
- 11.2.1.1. Overview
- 11.2.1.2. Product
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. financials (Based on Availability)
- 11.2.2. Eli Lilly and Company
- 11.2.2.1. Overview
- 11.2.2.2. Product
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. financials (Based on Availability)
- 11.2.3. Sanofi
- 11.2.3.1. Overview
- 11.2.3.2. Product
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. financials (Based on Availability)
- 11.2.4. BIOTON S.A.
- 11.2.4.1. Overview
- 11.2.4.2. Product
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. financials (Based on Availability)
- 11.2.5. Gan & Lee Pharmaceuticals Co Ltd.
- 11.2.5.1. Overview
- 11.2.5.2. Product
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. financials (Based on Availability)
- 11.2.6. Biocon
- 11.2.6.1. Overview
- 11.2.6.2. Product
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. financials (Based on Availability)
- 11.2.7. Tonghua Dongbao Pharmaceutical
- 11.2.7.1. Overview
- 11.2.7.2. Product
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. financials (Based on Availability)
- 11.2.8. Julphar
- 11.2.8.1. Overview
- 11.2.8.2. Product
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. financials (Based on Availability)
- 11.2.9. Wockhardt
- 11.2.9.1. Overview
- 11.2.9.2. Product
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. financials (Based on Availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
